¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"contact activation product"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • contact compound scan
    Á¢Ã˺¹ÇÕ½ºÄµ
  • contact dermatitis
    Á¢ÃËÇǺο°
  • contact gunshot wound
    Á¢»çÃÑ»ó
  • contact hypersensitivity
    Á¢Ã˰ú¹Î(Áõ)
  • contact immunotherapy
    Á¢Ã˸鿪¿ä¹ý
  • contact infection
    Á¢Ã˰¨¿°
  • contact inhibition
    Á¢Ã˾ïÁ¦
  • contact irradiation
    Á¢ÃËÁ¶»ç¹ý
  • contact lens
    ÄÜÅÃÆ®·»Áî, Á¢ÃË·»Áî
  • contact media
    Á¢Ã˸Ű³¹°
  • contact radiography
    ±ÙÁ¢¹æ»ç¼±ÃÔ¿µ(¼ú)
  • contact scan
    Á¢Ã˽ºÄµ
  • contact scanner
    Á¢Ã˽ºÄ³³Ê
  • contact stomatitis
    Á¢ÃËÀԾȿ°, Á¢Ã˱¸³»¿°
  • contact ulcer
    Á¢Ã˱˾ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • contact comfort
    Á¢ÃËÀ§¾È
  • contact dermatitis
    Á¢ÃËÇǺο°
  • contact hypersensitivity
    Á¢Ã˰ú¹Î
  • contact immunotherapy
    Á¢Ã˸鿪¿ä¹ý
  • contact infection
    Á¢Ã˰¨¿°
  • contact inhibition
    Á¢Ã˾ïÁ¦
  • contact irradiation
    Á¢ÃËÁ¶»ç¹ý
  • contact lens
    ÄÜÅÃÆ®·»Áî, Á¢ÃË·»Áî
  • contact media
    Á¢Ã˸Ű³¹°
  • contact radiography
    ±ÙÁ¢ÃÔ¿µ¼ú
  • contact scan
    Á¢Ã˽ºÄµ
  • contact scanner
    Á¢Ã˽ºÄ³³Ê
  • contact scanning
    Á¢Ã˽ºÄ³´×
  • contact stomatitis
    Á¢ÃËÀԾȿ°, Á¢Ã˱¸³»¿°
  • contact urticaria
    Á¢Ã˵ε巯±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • polyclonal B cell activation
    B¼¼Æ÷ ´Ù(¼ö)Ŭ·ÐȰ¼º, B¼¼Æ÷ ¿©·¯¹«¸®È°¼º
  • polyclonal activation
    ´Ù(¼ö)Ŭ·ÐȰ¼º, ¿©·¯¹«¸®È°¼º
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • c3, activation
    C3, Ȱ¼º (¡­üÀàõ)
  • complement activation
    º¸Ã¼È°¼ºÀÛ¿ë(¡­üÀàõíÂéÄ), º¸Ã¼È°¼ºÈ­.
  • complement activation
    º¸Ã¼È°¼ºÀÛ¿ë
  • energy of activation
    Ȱ¼ºÈ­¿¡³ÊÁö.
  • heat of activation
    Ȱ¼ºÈ­¿­(üÀàõûýæð)
  • islet-activation factor
    ¶û°Ô¸£Çѽº»ù Ȱ¼ºÀÎÀÚ, ¹éÀÏÇØ±Õµ¶¼Ò
  • macrophage,activation of
    Ȱ¼ºÈ­(üÀàõûù)
  • neutron activation analysis
    Áß¼ºÀÚ¹æ»çÈ­ºÐ¼®(~Û¯ÞÒûùÝÂà°).
  • photochemical activation
    ±¤È°¼ºÈ­(Ë´Ì· ËÛÌ´).
  • plasmin activation inhibitor
    Çö󽺹ÎȰ¼ºÈ­¾ïÁ¦Á¦(¡­üÀàõûùåäð¤ð¥)
  • polyclonal B cell activation
    B¼¼Æ÷ ´Ù(¼ö)Ŭ·ÐȰ¼º, B¼¼Æ÷ ¿©·¯¹«¸®È°¼º
  • polyclonal activation
    ´Ù(¼ö)Ŭ·ÐȰ¼º, ¿©·¯¹«¸®È°¼º
  • sleep activation
    ¼ö¸éºÎȰ(¹ý)(¡­Ý¥üÀÛö) ³úÆÄ(Òà÷î)ÀÇ .
  • thermal activation
    ¿­È°¼ºÈ­¹ÝÀÀ(æðüÀàõûù Úãëë).
  • tissue plasminogen activation
    Á¶Á÷ ÇöóÁî¹Ì°Õ Ȱ¼º
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • reciprocal activation
    »óº¸ Ȱ¼ºÈ­(ßÓÜÍüÀàõûù)
  • upstream activation sites
    À­ÂÊ È°¼ºÈ­(üÀàõûù)ÀÚ¸®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CD cadaver donor; canine distemper; canine dose; carbohydrate dehydratase; carbon dioxide; cardiac dise...
CGDE contact glow discharge electrolysis
CHS central hypoventilation syndrome; Chediak-Higashi syndrome; cholinesterase; chondroitin sulfate; com...
CL capillary lumen; cardiolipin; cell line; centralis lateralis; chemiluminescence; chest and left arm ...
CMNA complement-mediated neutrophil activation
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CMR contact micro radiography
CPS contact photosensitivity
BDP break down product
CPSC Consumer Product Safety Commission
DPOAE Distorsion product otoacoustic emissions
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • contact irradiation
    ±ÙÁ¢ Á¶»ç, ±ÙÁ¢ Á¶»ç¹ý
  • contact media
    Á¢ÃËÁ¦
  • contact mode
    Á¢ÃËÇü
  • contact potential difference
    Á¢ÃË ÀüÀ§Â÷
  • contact scan
    Á¢ÃË ½ºÄµ
  • contact surface
    Á¢Ã˸é
    °£È¤ »óÇÏ Ä¡¾Æ°£ ±³ÇÕ¸é Á¢ÃËÀ» °¡¸®Å°´Â °æ¿ìµµ ÀÖ´Ù.
  • contact time
    Á¢ÃË ½Ã°£
  • damaging contact
    À§ÇØ Á¢ÃË
  • final centric relation occlusal contact
    ÃÖÁ¾ Áß½ÉÀ§ ±³ÇÕ Á¢ÃË
  • heavy posterior contact
    ±¸Ä¡ºÎ °ú´Ù Á¢ÃË
    ±³ÇÕ ÀÌ»óÀ¸·Î ÀÎÇÑ ±¸Ä¡ºÎ °ú´Ù Á¢ÃËÀº ÅΰüÀý Àå¾Ö, ¶Ç Ä¡¾ÆÀÇ ½ÉÇÑ ¸¶¸ð°¡ ÀϾ ¼ö ÀÖ´Ù.
  • hydrogel contact lens
    ÇÔ¼ö ÄÜÅÃÆ® ·»Áî
  • immediate contact
    Á÷Á¢ Àü¿°
    Àü¿°¼º ÁúȯÀ» °¡Áø »ç¶÷¿¡°Ô °Ç°­ÇÑ »ç¶÷ÀÌ Á¢ÃËÇÏ¿© ±× °á°ú·Î¼­ º´ÀÌ ¿Å°ÜÁö´Â °Í.
  • initial contact
    ¿¹ºñ Á¢ÃË, Ãʱâ Á¢ÃË
    1. ÇϾÇÀÌ »ó¾ÇÀ» ÇâÇØ ¿Ã¶ó¿À¸é¼­ ´ëÇÕÄ¡°£¿¡ Á¦ÀÏ ¸ÕÀú ÀϾ´Â Á¢ÃË. Æó±¸ÇÒ ¶§ »óÇÏ¾Ç Ä¡¾Æ°£¿¡ ÀϾ´Â Á¢ÃËÀº ºñÁ¤»óÀûÀ̰ųª °£¼·ÀûÀÎ °ÍÀº ¾Æ´Ï´Ù. 2. ÅÎÀ» ´Ù¹°¾úÀ» ¶§ ÃÖÃÊ¿¡ ÀϾ´Â »ó¾Ç Ä¡¾Æ¿Í ÇÏ¾Ç Ä¡¾Æ¿ÍÀÇ Á¢ÃË.
  • initial occlusal contact
    Ãʱ⠱³ÇÕ Á¢ÃË
  • intercuspal contact
    ±³µÎ°£ Á¢ÃË
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
virus activation The mechanism by which latent viruses, such as genetically transmitted tumour viruses or prophages of lysogenic bacteria, are induced to replicate and are released as infectious viruses. It may be effected by various endogenous and exogenous stimuli, including B-cell lipopolysaccharides, glucocorticoid hormones, halogenated pyrimidines, ionizing radiation, ultraviolet light, and superinfecting viruses.
(12 Dec 1998)
cis activation <molecular biology> Activation of a gene by an activator located on the same chromosome i.e. Not by a diffusible product.
(18 Nov 1997)
complement activation The sequential activation of serum components c1 through c9, initiated by an erythrocyte-antibody complex or by microbial polysaccharides and properdin, and producing an inflammatory response.
(12 Dec 1998)
platelet activation A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable haemostatic plug.
(12 Dec 1998)
neutron activation analysis Activation analysis in which the specimen is bombarded with neutrons. Identification is made by measuring the resulting radioisotopes.
(12 Dec 1998)
neutrophil activation The process in which the neutrophil is stimulated by diverse substances, resulting in degranulation and/or generation of reactive oxygen products, and culminating in the destruction of invading pathogens. The stimulatory substances, including opsonised particles, immune complexes, and chemotactic factors, bind to specific cell-surface receptors on the neutrophil.
(12 Dec 1998)
EEG activation The low voltage, fast pattern of attentive wakefulness.
(05 Mar 2000)
trans-activation (genetics) Increased rate of gene expression directed by either viral or cellular proteins. These regulatory factors (diffusible gene products) act in trans -- that is, act on homologous or heterologous molecules of DNA. (cis-acting factors act only on homologous molecules.)
(12 Dec 1998)
energy of activation Energy that must be added to that already possessed by a molecule or molecules in order to initiate a reaction; usually expressed in the Arrhenius equation relating a rate constant to absolute temperature.
(05 Mar 2000)
enzyme activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1) activation by ions (activators); 2) activation by cofactors (coenzymes); and 3) conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme.
(12 Dec 1998)
juxtacrine activation Activation of target cells by membrane anchored growth factors, also used for activation of leucocytes by PAF bound to endothelial cell surface.
(18 Nov 1997)
feedback activation The activation of an enzyme by an end product of a biochemical pathway in which that enzyme plays a part. For example, the activation of factors VIII and V by thrombin during blood clotting.
(05 Mar 2000)
feed-forward activation The activation of an enzyme by a precursor of the substrate of that enzyme.
(05 Mar 2000)
upstream activation site A DNA sequence that regulates transcription like an enhancer but does notwork if its located downstream from a promoter.
(09 Oct 1997)
low-activation materials <radiobiology> In fission reactors, one is forced to deal with the radioactive byproducts of the fission process, but in fusion reactors one generally has a choice of what materials to expose to neutrons produced by the fusion process. A major problem for fusion reactors is developing materials (such as for the reactor vacuum vessel structure) which can be exposed to high levels of neutron bombardment without becoming permanently radioactive. Candidate structural materials which have relatively low induced radiactivation (generally relative to stainless steel) are known as low-activation materials, these include titanium, vanadium, and silicon-carbide.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • contact catalysis
    Á¢ÃË(Ã˸Å)ÀÛ¿ë
  • contact dermatitis
    Á¢ÃË ÇǺο°
  • contact electricity
    Á¢ÃËÀü±â
  • contact flying(flight)
    Á¢ÃË ºñÇà;À¯½Ã°èºñÇà
  • contact high
    °¨¿°(°£Á¢) µµÃë(¸¶¾àµµÃëÀÚ¿Í Á¢Çϰųª ¿¬±â³¿»õ·Î ÃëÇϱâ)
  • contact ingibition
    Á¢ÃËÀúÁö(¹è¾ç¼¼Æ÷°¡ ¼­·Î Á¢ÃËÇÏ¿© ±â´ÉÀÌ Á¤ÁöµÇ±â)
  • contact lens
    ÄÜÅÃÆ® ·»Áî
  • contact maker
    (Àü·ùÀÇ)Á¢Ã˱â
  • contact man
    (°Å·¡µîÀÇ)Áß°³ÀÚ;Á¤º¸Á¦°øÀÚ;(°ü°ø¼­µî¿¡ ´ëÇÑ)¼·¿ÜÀÚ;(½ºÆÄÀ̵îÀÇ)¿¬¶ô¿ø
  • contact metamorphism
    Á¢Ã˺¯¼ºÀÛ¿ë
  • contact mine
    Ã˹߼ö·Ú(±â·Ú,Áö·Ú)
  • contact paper
    ¹ÐÂø(ÀÎÈ­)Áö
  • contact potential
    Á¢ÃË ÀüÀ§Â÷
  • contact print
    ¹ÐÂø ÀÎÈ­
  • contact process
    (Ȳ»êÁ¦Á¶ÀÇ)Á¢Ã˹ý 0
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á